Rate of Uptake of Ivacaftor Use after U.S. Food and Drug Administration Approval among Patients Enrolled in the U.S. Cystic Fibrosis Foundation Patient Registry.

Abstract excerpt

RATIONALE: Chronic cystic fibrosis (CF) therapies have variable rates of prescribed use, and therapies are rarely prescribed to more than 80% of eligible patients. Ivacaftor was approved in the United States in January 2012 for patients ages 6 years and older with a G551D mutation in their CF gene. OBJECTIVES: To examine the rate of uptake and patterns of documented ivacaftor use among U.S. patients with CF...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aminophenols
• Share to Cystic Fibrosis